---
title: "A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients"
description: "To assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in HIV-infected patients with CD4 counts \\< 150 cells/mm3"
url: "https://www.clareohealth.com/clinical-trials/NCT00002438"
---

To assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in HIV-infected patients with CD4 counts \< 150 cells/mm3 who reside where histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.

## Key Facts

**ID:** NCT00002438
**Status:** COMPLETED
**Phase:** NA
**Type:** INTERVENTIONAL
**Sponsor:** Janssen, LP

## About This Study

This clinical trial tested itraconazole, a medication, to see if it can help prevent histoplasmosis, a fungal infection, in people living with HIV who have low immune cell counts. It focused on patients with CD4 counts below 150 cells/mm3 living in areas where histoplasmosis is common.

## Conditions

- HIV Infections
- Histoplasmosis

## Interventions

**DRUG: Itraconazole**


## Eligibility

Inclusion Criteria Patients must have: * HIV infection. * Residence in an area endemic for H. capsulatum. * Absolute CD4 count \< 150 cells/mm3.

## Who Can Participate

**Minimum age:** 13

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Infectious Diseases Research Clinic / Indiana Univ Hosp, Indianapolis, Indiana, United States
- Infectious Diseases of Indianapolis, Indianapolis, Indiana, United States
- Univ of Missouri at Kansas City School of Medicine, Kansas City, Missouri, United States
- Infectious Diseases Association / Research Med Ctr, Kansas City, Missouri, United States
- ASCC, Memphis, Tennessee, United States
- Dr Michael Threikeld, Memphis, Tennessee, United States
- Dr Mark A Pierce, Nashville, Tennessee, United States

## Contact Information

## Important Dates

**Last updated:** June 24, 2005

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have HIV and live in an area where histoplasmosis is common.
- Your CD4 count is below 150 cells/mm3, indicating a weakened immune system.
- You want to explore options for preventing fungal infections, especially if you have a history of other infections.

### Questions to Ask

- Am I eligible for this trial based on my current health and medications?
- What are the potential side effects of taking itraconazole?
- How does this treatment compare to other options I might have for preventing infections?
- What will my participation involve in terms of visits and tests?
- How long will I need to take the medication if I participate?
- What happens if I experience side effects during the trial?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT00002438)
